Furthermore, 6,554 subjects seronegative in 1987 (or 1992) baseline VCA/IgA test and free of NPC during follow-up were retested for VCA/IgA antibodies in 1997. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.